OS Therapies Inc(OSTX) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 27 at 5:40 PM ET (Korea 10/28 06:40)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -1.04 | Insider Own | 6.55% | Shs Outstand | 45.3M | Perf Week | -2.38% |
| Market Cap | 0.06B | Forward P/E | - | EPS next Y | 74.24% | Insider Trans | - | Shs Float | 43.7M | Perf Month | -25.45% |
| Enterprise Value | 0.06B | PEG | - | EPS next Q | -0.14 | Inst Own | 6.23% | Short Float | 6.45% | Perf Quarter | -16.89% |
| Income | -0.04B | P/S | - | EPS this Y | 24.74% | Inst Trans | 0.32% | Short Ratio | 4.86 | Perf Half Y | -24.54% |
| Sales | 0.00B | P/B | - | EPS next 5Y | - | ROA | -389.65% | Short Interest | 2.82M | Perf YTD | -12.14% |
| Book/sh | -0.26 | P/C | 274.12 | EPS past 3/5Y | -47.63% 67.91% | ROE | -914.04% | 52W High | -45.33% ($2.25) | Perf Year | -37.24% |
| Cash/sh | 0 | P/FCF | - | Sales past 3/5Y | - | ROIC | - | 52W Low | 6.96% ($1.15) | Perf 3Y | - |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -41.63% | Gross Margin | - | Volatility(W/M) | 5.91% 6.56% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.09 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 0.18 | EPS Q/Q | -8.86% | Profit Margin | - | RSI (14) | 28.79 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 0.18 | Sales Q/Q | - | SMA20 | -13.93% ($1.43) | Beta | -0.57 | Target Price | $8.5 |
| Payout | - | Debt/Eq | - | Earnings | 2026/8/14 | SMA50 | -22.49% ($1.59) | Rel Volume | 0.54 | Prev Close | $1.21 |
| Employees | 5 | LT Debt/Eq | - | EPS/Sales Surpr. | -12.36% - | SMA200 | -21.53% ($1.57) | Avg Volume(3M) | 0.58M | Price | $1.23 |
| IPO | 2024/8/1 | Option/Short | No/Yes | Trades | 588 | Volume | 315,857 | Change | 1.65% |
A clinical-stage biopharmaceutical company developing innovative immunotherapies for the treatment of osteosarcoma in children and other rare cancers.
Over the past 1 year, on the lower side
45% below its 1-year high.
Traded less than usual. That is 54% of its average volume.
OSTX has weak earnings and a weak balance sheet
Review management risk carefully before investing
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +24.7% this year.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Tap to view numbers
No dividend
There is no profit to distribute yet.
Institutions barely hold it
Institutions hold 6.2%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #400 of 594 in the industry
Based on market cap of $58M.
OSTX#400 OS Therapies Inc $58M PER - 
HRTX#401 Heron Therapeutics Inc $57M PER - 
APLM#402 Apollomics Inc $57M PER - 
CLNN#403 Clene Inc $56M PER - 
XBIT#404 XBiotech Inc $56M PER - 
FAQ
What kind of company is OSTX?
OSTX belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of OSTX?
The market cap of OSTX is approximately $58M, ranking 4,765 within its sector.
What is the 52-week high and low for OSTX?
OSTX has recorded a 52-week high of $2.25 and a low of $1.15.
